Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia
β Scribed by Rebecca L. Auer; Jane Starczynski; Suzanne McElwaine; Francesco Bertoni; Adrian C. Newland; Chris D. Fegan; Finbarr E. Cotter
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 158 KB
- Volume
- 43
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
β¦ Synopsis
Deletions of 11q in chronic lymphocytic leukemia (CLL) are usually associated with progressive disease and poor prognosis. A novel translocation within the previously identified 11q minimal region has been defined in a patient with CLL. The breakpoint is between genes POU2AF1 and BTG4. POU2AF1 is a B-cell-specific transcriptional coactivator, and BTG4 is a member of the BTG family of negative regulators of the cell cycle, making both of them good candidate genes for the pathogenesis of 11qΓ CLL. POU2AF1 was observed to be differentially expressed in the cells of patients with CLL compared to its expression in normal B cells in the absence of mutations. This may reflect ongoing stimulation and active accessory signaling in CLL cells. BTG4 could contribute to CLL pathogenesis following inactivation by haploinsufficiency.
π SIMILAR VOLUMES
The t( 14; 19)(q32.3;q I 3. I ) is a recurring translocation found in the neoplastic cells of some patients with chronic lymphocytic leukemia (CLL). W e have previously cloned the translocation breakpoint junction present in the leukemic cells from one such patient. In the present study, we have clo
## Abstract DNA from white blood cells from healthy controls demonstrates a restriction fragment length polymorphism (RFLP) of the Haβras oncogene locus after cleavage with the restriction enzymes BamH I or MspI plus HpaII, representing frequent and rare alleles. We have studied the RFLP of 15 pati
The cyclin D1/PRAD1 oncogene, a key regulator of the G 1 phase of the cell cycle, has been incriminated in the pathogenesis of human neoplasia. Cyclin D1 was also demonstrated to be identical to the long-sought bcl-1 oncogene in B-cell malignancies with the t(11;14)(q13;q32) translocation. We report